Document Classification

Section Type: CONCLUSIONS

Text: At week 12, subjects receiving tolterodine ER plus alpha-blocker had significantly greater improvements versus placebo plus alpha-blocker in 24-h micturitions (-1. 8 vs -1. 2 ; p = 0. 0079) and daytime micturitions (-1. 3 vs -0. 8 ; p = 0. 0123) ; 24-h urgency episodes (-2. 9 vs -1. 8 ; p = 0. 0010), daytime urgency episodes (-2. 2 vs -1. 4 ; p = 0. 0017), and nocturnal urgency episodes (-0. 5 vs -0. 3 ; p = 0. 0378) ; frequency-urgency sum (-7. 8 vs -5. 1 ; p = 0. 0065) ; IPSS storage subscale (-2. 6 vs -2. 1 ; p = 0. 0370) ; and OAB-q symptom bother scale (-17. 9 vs -14. 4 ; p = 0. 0086) and coping domain (15. 4 vs 12. 4 ; p = 0. 0491).